Aktis Oncology, Inc. (AKTS)
The price, the headline numbers and the latest news, in one place.
Aktis Oncology, Inc. (AKTS) Stock Price, Analysis & Data
No data available
| Bid | 18.82 |
| Market Cap | 1.48B |
| Revenue (ttm) | 10.1M |
| Net Income (ttm) | -73.1M |
| 0.00 | |
| -1.32 | |
| n/a | |
| -12.84 | |
| P/B (ttm) | 3.04 |
| P/S (ttm) | 147.34 |
| Earnings Date | Nov 12, 2026 |
| Ask | 34.36 |
| Volume | 45,351 |
| Avg. Volume (20D) | 388,131 |
| Open | 27.29 |
| Previous Close | 26.92 |
| Day's Range | 26.35 - 27.66 |
| 52-Week Range | 14.72 - 34.19 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AKTS
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer,...
Financial Performance
In 2025, Aktis Oncology's revenue was 6.5M, an increase of 336.92% compared to the previous year's 1.49M. Earnings were -63.73M, an increase of 44.91%.
Financial StatementsEarnings Surprise
- Revenue of $3.23M misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.44 misses estimates by -0.01, with -214.29% YoY decline.
Analysts project revenue of ... Upgrade
3 months ago · Simply Wall St.
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price ReboundWhat recent performance says about Aktis Oncology Aktis Oncology (AKTS) has drawn fresh attention after recent trading, with the stock up 6.4% on the day and 9.3% over the past week, even as it is dow...
